Which GLP-1 Drugs Cause the Most Metabolic Side Effects? An FDA Database Analysis

Pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS) database. Researchers extracted all metabolic and nutritional adverse event reports for seven GLP-1 receptor agonists from their respective launch dates through Q2 2023. Four statistical methods were used to identify safety signals: reported odds ratio (ROR), proportional reporting ratio (PRR), Empirical Bayesian Geometric Mean, and Bayesian Confidence Propagation Neural Network. Time-to-onset analysis was also performed.

With tens of millions of people now taking GLP-1 drugs, understanding their real-world side effect patterns is critical. This study highlights dehydration as a particularly important — and potentially underrecognized — risk across all major GLP-1 drugs. Dehydration can lead to kidney injury, electrolyte imbalances, and hospitalization, especially in elderly patients or those on diuretics.

As GLP-1 drugs expand from diabetes into obesity, MASH, cardiovascular disease, and addiction, their safety profile becomes even more important. This is the largest pharmacovigilance comparison of metabolic side effects across GLP-1 drugs to date. The dehydration finding is particularly relevant — patients on these drugs often eat and drink less, and the combination of reduced fluid intake with the drugs' gastrointestinal effects could create a dangerous dehydration risk that needs proactive management.

FAERS is a voluntary reporting system with inherent biases — popular drugs get more reports, and reporting rates vary over time. The data can't establish causation, only associations. Media attention on semaglutide and tirzepatide may inflate their report counts. No adjustment for patient demographics, comorbidities, or concomitant medications. Under-reporting is a known limitation of all pharmacovigilance databases.